Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank64
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-75.37M
↑ 39% vs avg
Percentile
P64
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
$-122.93M
Historical baseline
PeriodValueYoY Change
2025$-75.37M+40.9%
2024$-127.63M-37.6%
2023$-92.72M+38.0%
2022$-149.67M-32.7%
2021$-112.83M+29.6%
2020$-160.38M+16.0%
2019$-191.03M-18.3%
2018$-161.48M-118.9%
2017$-73.78M+12.6%
2016$-84.46M-